HC Wainwright Has Strong Estimate for BioCardia Q3 Earnings

BioCardia, Inc. (NASDAQ:BCDA) – Investment analysts at HC Wainwright raised their Q3 2026 earnings estimates for BioCardia in a research note issued on Thursday, August 13th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of ($0.15) per share for the quarter, up from their previous estimate of ($0.18). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for BioCardia’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for BioCardia’s Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.58) EPS and FY2028 earnings at ($0.39) EPS.

BioCardia (NASDAQ:BCDA) last posted its earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05.

A number of other equities research analysts also recently issued reports on the company. Wall Street Zen upgraded BioCardia from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Research raised BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, BioCardia has an average rating of “Hold” and a consensus price target of $25.00.

BioCardia Price Performance

BCDA opened at $0.94 on Monday. The company has a fifty day moving average price of $0.94 and a 200-day moving average price of $1.07. The firm has a market capitalization of $10.70 million, a P/E ratio of -1.47 and a beta of 0.49. BioCardia has a one year low of $0.75 and a one year high of $2.29.

Insiders Place Their Bets

In related news, Director Simon H. Stertzer bought 39,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $39,000.00. Following the completion of the transaction, the director directly owned 166,338 shares in the company, valued at $166,338. This trade represents a 30.63% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have purchased 136,800 shares of company stock valued at $128,324 over the last quarter. Company insiders own 17.40% of the company’s stock.

Hedge Funds Weigh In On BioCardia

A number of institutional investors have recently made changes to their positions in BCDA. Cetera Investment Advisers bought a new position in shares of BioCardia in the 2nd quarter worth $40,000. DRW Securities LLC bought a new stake in shares of BioCardia during the 4th quarter worth $72,000. Finally, Geode Capital Management LLC lifted its holdings in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after acquiring an additional 27,263 shares during the last quarter. Institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.